StockUS listing USDNTHNASDAQHealthcareEarnings Deterioration

Dianthus Therapeutics Inc.(DNTH) Stock Analysis | Healthcare

USD --+0.00%
Reward36Moderate
Risk16Low
75%Data
Revenue growing 206% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 4.76Bn
Reward Ratingⓘ36 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ16 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on DNTH to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Dianthus Therapeutics Inc.?

, a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.

AI Brief Pro

The brief on Dianthus Therapeutics Inc.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Dianthus Therapeutics Inc.?

, a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 4.76B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (36)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.256
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
17167,166 shares
$15.7M
0
3-6months
319,342 shares
$2.2M
0
6-9months
0
0
9-12months
0
0